アラバマ州における多発性骨髄腫の臨床試験
アラバマ州内の拠点で、多発性骨髄腫に関する22件の研究が参加者を募集しています。
アラバマ州内の都市
公式研究テキスト（英語）
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- University of Alabama At Birmingham Hospital, Birmingham
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT04973605A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Alabama Oncology, Birmingham
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07518186A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- University of Alabama Birmingham, Birmingham
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT04634552A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
- University of Alabama at Birmingham Hospital, Birmingham
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/23更新 · NCT07116616TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham
被験者募集中第2相
12歳以上 · 全性別 · 2026/09/22更新 · NCT02693535A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- University of Alabama at Birmingham, Birmingham
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/15更新 · NCT06615479Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/14更新 · NCT06297226A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- Infirmary Health - Diagnostic & Medical Clinic (DMC), Mobile
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/09更新 · NCT06980480A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/02更新 · NCT06988488MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Infirmary Cancer Care, Mobile
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/24更新 · NCT06152575AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Birmingham
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/17更新 · NCT05850234A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Clearview Cancer Institute, Huntsville
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/06更新 · NCT07284758A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/16更新 · NCT06121843Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
被験者募集中第2相
19歳以上 · 全性別 · 2026/06/04更新 · NCT06974786A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Mobile
被験者募集中第3相
18歳以上 · 全性別 · 2026/04/22更新 · NCT06679101A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/18更新 · NCT06153251Study of BMS-986453 in Newly Diagnosed Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
被験者募集中第1相
19歳以上 · 全性別 · 2026/02/13更新 · NCT07333261Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
- University of Alabama at Birmingham, Birmingham
被験者募集中第2相
18歳以上 · 全性別 · 2025/12/31更新 · NCT04991103Prehabilitation Feasibility Among Older Adults Undergoing Transplantation
- Kirklin Clinic of UAB Hospital, Birmingham
被験者募集中
60歳以上 · 全性別 · 2025/12/24更新 · NCT05642884Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
- Kirklin Clinic of UAB Hospital, Birmingham
被験者募集中観察研究
50歳以上 · 全性別 · 2025/12/08更新 · NCT05556928CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
被験者募集中第1相
18歳以上 · 全性別 · 2025/09/25更新 · NCT05722418A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
- UAB Comprehensive Cancer Center, Birmingham
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/09/05更新 · NCT05372354ClinicalTrials.govより、2026/10/04時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。